Adiponectin: An independent risk factor for coronary heart disease in men in the Framingham offspring Study

Atherosclerosis

Volumn 217, Issue 2, 2011, Pages 543-548

  Ai, Masumi ^a   Otokozawa, Seiko ^a   Asztalos, Bela F ^a   White, Charles C ^d   Cupples, L Adrienne ^b,c   Nakajima, Katsuyuki ^a   Lamon Fava, Stefania ^a   Wilson, Peter W ^c   Matsuzawa, Yuji ^d   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b BOSTON UNIVERSITY   (United States)

^c FRAMINGHAM HEART STUDY   (United States)

^d Sumitomo General Hospital   (Japan)

Author keywords

Adiponectin; Coronary heart disease; Framingham offspring Study; Obesity; Risk factor

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE;

ADIPONECTIN; AGED; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; CORONARY DISEASE; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MASSACHUSETTS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; TIME FACTORS; UP-REGULATION;

EID: 79960699067     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.05.035     Document Type: Article

References (33)

1. Ouchi N., Kihara S., Arita Y., et al. Adiponectin: an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signaling through a cAMP-dependent pathway. Circulation 2000, 102:1296-1301.
2. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
3. Yamauchi T., Kamon J., Waki H., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003, 278:2461-2468.
4. Kumada M., Kihara S., Sumitsuji S., et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003, 23:85-89.
5. Wolk R., Berger P., Lennon R.J., et al. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J 2007, 28:292-298.
6. Pischon T., Girman C.J., Hotamisligil G.S., et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
7. Maahs D.M., Ogden L.G., Kinney G.L., et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation 2005, 111:747-753.
8. Sattar N., Wannamethee G., Sarwar N., et al. Adiponectin and coronary heart disease; a prospective study and meta-analysis. Circulation 2006, 114:623-629.
9. Kizer J.R., Barzilay J.I., Kuller L.H., Gottdiener J.S. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab 2008, 93:3357-3364.
10. Dekker J.M., Funahashi T., Nijpels G., et al. Prognostic value of adiponectin for cardiovascular disease and mortality. J Clin Endocrinol Metab 2008, 93:1489-1496.
11. Lindsay R.S., Resnick H.E., Zhu J., et al. Adiponectin and coronary heart disease: the strong heart study. Arterioscler Thromb Vasc Biol 2005, 25:e15-e16.
12. Lawlor D.A., Davey Smith G., Ebrahim S., Thompson C., Sattar N. Plasma adiponectin levels are associated with insulin resistance, but do not predict future risk of coronary heart disease in women. J Clin Endocrinol Metab 2005, 90:5677-5683.
13. Kannel W.B., Feinleib M., McNamara P.M., Garrison R.J., Castelli W.P. An investigation of coronary heart disease in families. The Framingham offspring Study. Am J Epidemiol 1979, 110:281-290.
14. Asztalos B.F., Cupples L.A., Demissie S., et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham offspring Study. Arterioscler Thromb Vasc Biol 2004, 24:2181-2187.
15. Nishimura A., Sawai T. Determination of adiponectin in serum using a latex particle-enhanced turbidimetric immunoassay with an automated analyzer. Clin Chim Acta 2006, 371:163-168.
16. Snijder M.B., Heine R.J., Seidell J.C., et al. Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: the Hoorn study. Diabetes Care 2006, 29:2498-2503.
17. Nelson R.G., Sievers M.L., Knowler W.C., et al. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 1990, 81:987-995.
18. Matsuhisa M., Yamasaki Y., Emoto M., et al. A novel index of insulin resistance determined from the homeostasis model assessment index and adiponectin levels in Japanese subjects. Diabetes Res Clin Pract 2007, 77:151-154.
19. Dieplinger B., Gegenhuber A., Poelz W., Haltmayer M., Mueller T. Prognostic value of increased adiponectin plasma concentrations in patients with acute destabilized heart failure. Clin Biolchem 2009, 42:1190-1193.
20. Schnabel R., Messow C.M., Lubos E., et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtherogGene study. Eur Heart J 2008, 29:649-657.
21. Menon V., Li L., Wang X., et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol 2006, 17:2599-2606.
22. Antoniades C., Antonopoulos A.S., Tousoulis D., Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009, 10:269-279.
23. Esposito K., Pontillo A., Di Palo C., et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003, 289:1799-1804.
24. Yatagai T., Nishida Y., Nagasaka S., et al. Relationship between exercise training-induced increase in insulin sensitivity and adiponectinemia in healthy men. Endocr J 2003, 50:233-238.
25. Miyazaki Y., Mahankali A., Wajcberg E., et al. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004, 89:4312-4319.
26. Yang W.S., Jeng C.Y., Wu T.J., et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002, 25:376-380.
27. Phillips S.A., Ciaraldi T.P., Kong A.P., et al. Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. Diabetes 2003, 52:667-674.
28. Westphal S., Borucki K., Taneva E., Makarova R., Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis 2007, 193:361-365.
29. Lamon-Fava S., Diffenderfer M.R., Barrett P.H., et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apo B-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008, 28:1672-1678.
30. Sugiyama S., Fukushima H., Kugiyama K., et al. Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. Atherosclerosis 2007, 194:e43-e51.
31. Sakamoto K., Sakamoto T., Ogawa H. The effect of 6 months of treatment with pravastatin on serum adiponection concentrations in Japanese patients with coronary artery disease and hypercholesterolemia: a pilot study. Clin Ther 2006, 28:1012-1021. Kumamoto Joint Research on Hypercholesterolemia Investigators.
32. Nakano Y., Tajima S., Yoshimi A., et al. A novel enzyme-linked immunosorbent assay specific for high-molecular-weight adiponectin. J Lipid Res 2006, 47:1572-1582.
33. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol rationale and study design. The atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides: impact on global health outcomes (AIM-HIGH). Am Heart J 2011, 161. AIM-HIGH Investigators, (pp. 4711-477).